Evoke Pharma, Inc. filed its 10-K on Mar 21, 2023 for the period ending Dec 31, 2022. In this report its auditor, BDO LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.47 USD | 0.00% | -2.08% | -55.25% |
Apr. 24 | Transcript : Evoke Pharma, Inc. - Special Call | |
Mar. 21 | Evoke Pharma, Inc. Announces Board Changes as of March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.25% | 3.98M | |
+32.95% | 700B | |
+26.51% | 569B | |
-4.97% | 358B | |
+18.83% | 330B | |
+3.54% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+6.70% | 161B |
- Stock Market
- Equities
- EVOK Stock
- News Evoke Pharma, Inc.
- Evoke Pharma, Inc. Auditor Raises 'Going Concern' Doubt